The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH 2023 | The role of transplantation in MPNs & factors to consider when selecting patients for transplant
Claire Harrison, MD, FRCP, FRCPath, Guy’s & St Thomas’ NHS Foundation Trust, London, UK, discusses the role of stem cell transplantation in myeloproliferative neoplasms (MPNs), emphasizing that this approach is limited to patients with myelofibrosis (MF) or accelerated/blast-phase disease. Prof. Harrison further highlights how novel combination approaches may impact the role of transplant in MF, and explains the optimal time to take patients to transplant. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
